MedTrace Logo

Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib

NCT02786342 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2021-02-26

No results posted yet for this study

Summary

Sorafenib represents the standard care for advanced hepatocellular carcinoma (HCC). However, molecular predictors of sorafenib efficacy have not yet been identified.

The primary aim of the study is to validate the prognostic or predictive role of eNOS,Ang2, HIF-1, VEGF and VEGFR polymorphisms in relation to clinical outcome (progression-free survival, PFS) of HCC patients treated with sorafenib.

Conditions

Interventions

PROCEDURE

blood sample collection

Sponsors & Collaborators

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Andrea Casadei-Gardini, MD · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-15
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786342 on ClinicalTrials.gov